Tucatinib Demonstrates Survival Benefit in HER2+ Breast Cancer, FDA Submission Impending
December 12th 2019In the phase II HER2CLIMB trial, a 34% reduction in the risk of death was observed with the addition of tucatinib to the combination of trastuzumab and capecitabine in patients with heavily pretreated unresectable locally advanced or metastatic HER2-positive breast cancer compared to the combination alone, according to results from the phase II HER2CLIMB trial presented at the 2019 San Antonio Breast Cancer Symposium.
Read More
S-1 Shows Significant Improvement in iDFS for HR+, HER2-Breast Cancer
December 12th 2019Japanese patients with HR-positive, HER2-negative breast cancer had a significant improvement in invasive disease-free survival with the addition of the novel oral fluoropyrimidine derivative S-1, according to findings from the phase III POTENT trial presented at the 2019 San Antonio Breast Cancer Symposium.
Read More
Responses Observed With T-DXd May Change Standard of Care in Advanced HER2+ Breast Cancer
December 11th 2019In heavily pretreated patients with advanced HER2-positive breast cancer, trastuzumab deruxtecan induced a confirmed objective response rate of almost 61% and a durable benefit, according to results from the phase II DESTINY-Breast01 trial presented at the 2019 San Antonio Breast Cancer Symposium.
Read More
Daratumumab Leads to PFS Improvement in Patients With Transplant-Ineligible Myeloma
December 11th 2019A significant proportion of patients with transplant-ineligible newly diagnosed multiple myeloma alive and progression free after >3 years following treatment with daratumumab in addition to standard first-line therapy, according to updated safety and efficacy findings from the randomized ALCYONE study.
Read More
Impressive Results Continue With Updated Data on bb21217 in Multiple Myeloma
December 11th 2019In the phase I CRB-402 study, patients with heavily pretreated relapsed/refractory multiple myeloma and minimal residual disease negativity had very good partial responses to the anti-BCMA CAR T cell therapy bb21217, according to updated results presented at the 2019 American Society of Hematology Annual Meeting.<br />
Read More
In the phase III BELIEVE trial, clinically meaningful and durable transfusion burden reduction were observed with luspatercept in the majority of adult patients with β-thalassemia who require regular red blood cell. Additionally, dose levels were not associated with by incidence of adverse events, and these AEs decreases overtime without affecting treatment modification or continuation.
Read More
Bispecific Antibody Demonstrates Antitumor Activity in Heavily Pretreated NHL
December 11th 2019Treatment with REGN1979, a human anti-CD20 × anti-CD3 bispecific IgG4 antibody, showed high clinical activity and tolerability in heavily pretreated patients with relapsed/refractory B-cell non-Hodgkin lymphoma.<br />
Read More
BET Inhibitor Combination Induces Spleen and Symptom Responses in Myelofibrosis
December 11th 2019CPI-0610, a selective and potent oral bromodomain and extra-terminal domain inhibitor, induced spleen and symptom responses as early as 12 weeks in combination with the JAK inhibitor ruxolitinib in patients with JAK inhibitor-naïve myelofibrosis, according to the preliminary findings from the phase II MANIFEST trial presented at the 2019 ASH Annual Meeting.
Read More
Across Subtypes of B-cell NHL, REGN1979 Produces Promising Responses
December 11th 2019Heavily pretreated patients with relapsed/refractory B-cell non-Hodgkin lymphoma demonstrated antitumor activity when treated with varying dose levels of the human IgG4-based anti-CD20 × anti-CD3 bispecific monoclonalantibody, REGN1979.
Read More
GRIFFIN Follow-Up Shows Promising Responses With Daratumumab plus VRD
December 10th 2019Updated results of the GRIFFIN trial revealed that the addition of daratumumab to a standard-of-care regimen used in the treatment of newly diagnosed multiple myeloma met the trials primary end point of higher rates of stringent complete response in patients who are eligible for transplant.
Read More
Navitoclax Shows Activity in Ruxolitinib-Resistant Patients With Myelofibrosis
December 10th 2019Patients with primary or secondary myelofibrosis who developed resistance to ruxolitinib in the frontline setting, showed clinically meaningful spleen responses and improvements in symptoms with the addition of navitoclax to ruxolitinib, according to findings from a phase II study presented at the 2019 ASH Annual Meeting.
Read More
CC-486 Maintenance Extends OS in Older Patients With Acute Myeloid Leukemia
December 10th 2019An extended media overall survival of 9.9 months was achieved with CC-486 maintenance treatment compared with placebo for older patients with acute myeloid leukemia in first remission, according to findings from the phase III QUAZAR AML-001 trial presented at the 2019 American Society of Hematology Annual Meeting.<br /> <br />
Read More
Acalabrutinib Sustains Benefit In Patients With R/R CLL After 42 Months
December 10th 2019Ongoing benefits of 42 months were observed with Bruton’s tyrosine kinase inhibitor acalabrutinib treatment in patients with relapsed/refractory chronic lymphocytic leukemia, according to long-term follow-up data from the phase I/II ACE-CL-001 study reported at the 2019 American Society of Hemetology Annual Meeting.
Read More
Vecabrutinib Shows Evidence of Clinical Activity in Patients With B-Cell Malignancies
December 10th 2019Stable disease status was achieved in patients with b-cell malignancies through treatment with vecabrutinib, a reversible, noncovalent Bruton’s tyrosine kinase inhibitor, without producing any grade ≥3 treatment-related adverse events, according to data presented at the 2019 American Society of Hematology Annual Meeting and Exposition.
Read More
42-Month Follow-Up Data of Acalabrutinib Monotherapy in R/R CLL
December 10th 2019<br /> Richard R. Furman, MD, professor of medicine, Morton Coleman, MD Distinguished Professor of Medicine, director, Chronic Lymphocytic Leukemia Research Center, Weill Cornell Medicine, and attending physician, NewYork-Presbyterian Hospital, discusses the 42-month follow-up data of acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia.
Watch
Long-Term Follow-Up Supports Early Use of Ibrutinib in CLL
December 10th 2019Data from up to 6 years of long-term follow-up shows better progression-free survival, overall survival, objective response rates, and sustained efficacy for patients with chronic lymphocytic leukemia who receive single-agent ibrutinib in earlier lines of treatment, including those with high-risk prognostic factors. According to the poster presented by Paul M. Barr, MD, Division of Hematology/Oncology, Wilmot Cancer Institute, University of Rochester, Rochester, NY, during the 2019 American Society of Hematology Annual Meeting, first-line ibrutinib yielded deeper responses over time with 30% complete responses versus 10% to 12% CR for later lines of treatment.
Read More
Liso-Cel Shows Promising Clinical Activity and Safety in CLL/SLL
December 9th 2019Patients with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma who previously progressed on ibrutinib, responded well to treatment the CD19-directed CAR T-cell therapy lisocabtagene maraleucel and had manageable toxicity, according to updated findings from the phase I/II TRANSCEND CLL 004 study presented at the 2019 American Society of Hematology Annual Meeting and Exposition.
Read More
Higher Response Elicited With Initial Higher-Dose Duvelisib in Patients With R/R PTCL
December 9th 2019The administration of a higher initial dose of duvelisib at 75 mg BID led to a higher overall response rate of 62% compared with 40% in patients with relapsed/refractory peripheral T-cell lymphoma who received 25 mg BID, according to data from the dose-optimization phase of the PRIMO trial presented at the 2019 American Society of Hematology Annual Meeting.<br />
Read More
Zanubrutinib Highly Effective in CLL/SLL, Despite Presence of High-Risk Cytogenetics
December 9th 2019In the SEQUOIA trial, zanubrutinib, a Bruton’s tyrosine kinase inhibitor, showed continued high overall response rates for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, regardless of deletion 17p status, according to findings presented at the American Socitey of Hematology Annual Meeting and Exposition.
Read More
In the final analysis of the GADOLIN study in patients with rituximab-refractory indolent non-Hodgkin lymphoma, the combination of obinutuzumab plus bendamustine reduced the risk of progression or death by 43% compared with bendamustine alone. In patients with follicular lymphoma, the reduction was 49%.
Read More
LOXO-305 Shows High Efficacy in Patient With Heavily Pretreated B-cell Malignancies
December 9th 2019Treatment with LOXO-305 prompted responses from more than half of patients with heavily pretreated B-cell malignancies, including patients with resistance or intolerance to other BTK inhibitors or BCL2 inhibitors, according to findings from the phase I/II BRUIN trial presented at the 2019 American Society of Hematology Annual Meeting and Exposition.
Read More
Lenalidomide/Obinutuzumab Elicits 100% ORR in Rituximab-Refractory Indolent Non-Hodgkin Lymphoma
December 9th 2019A 100% overall response rate was achieved with the combination of lenalidomide and obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma that was refractory to rituximab, according to findings of a single-arm, phase I/II trial presented at the 2019 American Society of Hematology Annual Meeting and Exposition.<br />
Read More
Findings from a subgroup analysis of the phase III AUGMENT trial of patients aged 70 or older with indolent non-Hodgkin lymphoma showed a 34% reduction in the risk of disease progression or death compared with rituximab plus placebo, according data presented at the 2019 American Society of Hematology Annual Meeting and Exposition.<br />
Read More
Triplet Therapy Induced CR in R/R CLL
December 9th 2019In a phase I/II dose escalation study, there was a complete remission rate of 44% in patients with relapsed/refractory chronic lymphocytic leukemia receiving umbralisib, ublituximab, and venetoclax, according to findings presented at the 2019 ASH Annual Meeting.
Read More
Fixed-Duration Venetoclax Plus Obinutuzumab Improves PFS With High Undetectable MRD Rates in CLL
December 9th 2019Fixed-duration treatment with the combination of venetoclax plus obinutuzumab results in superior progression-free survival and high rates of undetectable minimal residual disease in patients with previously untreated chronic lymphocytic leukemia than chlorambucil plus obinutuzumab.
Read More
Bendamustine/Rituximab as Induction Therapy in MCL
December 9th 2019<br /> Diego Villa, MD, MPH, clinical associate professor, Division of Medical Oncology, The University of British Columbia, discusses a retrospective analysis evaluating bendamustine and rituximab as induction therapy in both transplant eligible and ineligible patients with mantle cell lymphoma. <br />
Watch
High Rates of CR Observed in Follicular Lymphoma With Triplet Regimen
December 8th 2019Patients with relapsed/refractory follicular lymphoma showed durable responses with the combination of polatuzumab-vedotin, obinutuzumab, and lenalidomide, according to results presented at the 2019 ASH Annual Meeting.
Read More
Obinutuzumab Plus Lenalidomide Shows Promise in High Tumor Burden Follicular Lymphoma
December 8th 2019Obinutuzumab combined with lenalidomide resulted in early and very high complete response rates in previously untreated patients with follicular lymphoma in a single-center phase II study. At a median follow-up of 25 months, the 2-year progression-free survival was 96%.
Read More